The SOPHiA DDM™ Platform will help Laboratorio
Curie advance its research into BRCA gene mutations
BOSTON and ROLLE, Switzerland, Sept. 13,
2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
a cloud-native software company and a leader in data-driven
medicine, has expanded its relationship with Laboratorio
Curie, a leading laboratory located in the capital city of
Paraguay. Laboratorio Curie is now
live on the SOPHiA DDM™ Platform and will use the technology to
deploy a new test that will identify BRCA gene mutations.
Discoveries made using this test aim to enable Laboratorio Curie to
support the increased use of precision medicine for hereditary
cancers within the country.
Laboratorio Curie has been a staple in Paraguay for more than 25 years and has been
recognized nationally for its high level of scientific research.
Since 2022 the Lab has worked with SOPHiA GENETICS to examine
variants associated with hereditary cancers and the expansion of
its relationship with SOPHiA GENETICS will allow the Lab to advance
its existing research. With the SOPHiA DDM™ Platform, Laboratorio
Curie will use next-generation sequencing (NGS) to screen for
mutations in the BRCA genes which have been shown to be linked to
an increased risk of several cancers, most notably, breast and
ovarian cancer1.
"At Laboratorio Curie our mission is research, even behind the
most clinical analyses. It is this passion that guides us to
advance science and work every day to discover ways to make a
difference in people's lives," said Dra. Filartiga, Lab
Director, Laboratorio Curie. "Thanks to the commitment,
dedication, and effort of our team, today we are considered an
outstanding benchmark in Paraguay.
Being pioneers in precision medicine in cancer through genomics and
hand in hand with SOPHiA GENETICS is a goal achieved with
effort and perseverance, and we are proud to have the trust and
respect of the medical community."
The identification of BRCA mutations via NGS testing produces a
vast amount of data that can be time-consuming and complex to
analyze. The SOPHiA DDM™ Platform is a technology agnostic
application that uses artificial intelligence (AI) to efficiently
analyze and interpret raw NGS data. The SOPHiA DDM™ Platform will
provide Laboratorio Curie with accurate and analyzed results
in less than two days, accelerating reporting and data-driven
decision-making for researchers.
"By using the SOPHiA DDM™ Platform, Laboratorio Curie can ensure
speed and accuracy of its NGS testing to best support
investigations into BRCA-associated cancers. Additionally, the Lab
will be able to amass a database of BRCA research that will map a
more holistic view of how BRCA is impacting South Americans." said
Ricardo Mendonca Filho, Ph.D.,
Managing Director, LAPAC, SOPHiA GENETICS.
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect on X (formerly known
as Twitter), LinkedIn, Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on X (formerly known as
Twitter), LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures, unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the
appropriate product information for your country of
residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains statements
that constitute forward-looking statements. All statements other
than statements of historical facts contained in this press
release, including statements regarding our future results of
operations and financial position, business strategy, products, and
technology, as well as plans and objectives of management for
future operations, are forward-looking statements. Forward-looking
statements are based on our management's beliefs and assumptions
and on information currently available to our management. Such
statements are subject to risks and uncertainties, and actual
results may differ materially from those expressed or implied in
the forward-looking statements due to various factors, including
those described in our filings with the U.S. Securities and
Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
[1]
https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet
View original content to download
multimedia:https://www.prnewswire.com/news-releases/laboratorio-curie-expands-relationship-with-sophia-genetics-301926317.html
SOURCE SOPHiA GENETICS